Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flurbiprofen + lidocaine
- Development stage
- Unknown
- Lead developer
- Boots UK
- Modality
- Small Molecules
- Administration
- Intravenous, Topical, Transdermal
01
Overview
A combination drug that pairs flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID), with lidocaine, a local anesthetic. Flurbiprofen works by inhibiting cyclooxygenase-1 and -2 enzymes, decreasing prostaglandin synthesis in peripheral tissues, while lidocaine blocks sodium channels in nerve membranes. This dual mechanism provides more effective pain relief than either agent alone. The combination is used to reduce propofol injection pain and for topical management of various pain conditions.
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NaV (Voltage-gated sodium channels)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on flurbiprofen + lidocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flurbiprofen + lidocaine.